NCT02254135View on ClinicalTrials.gov

Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BEA 2180 BR in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

January 31, 2007

Conditions
Healthy
Interventions
DRUG

BEA 2180 BR - rising dose

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY